Analysis of Percutaneous Ablations for Cancer Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01563679|
Recruitment Status : Completed
First Posted : March 27, 2012
Last Update Posted : May 28, 2014
This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies.
Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.
|Condition or disease|
The efficacy of the percutaneous and transarterial treatments for solid tumors will be studied. Prospective study on patients who receive percutaneous locoregional therapies, including radiofrequency ablation (RFA), cryoablation, microwave ablation, IRE and chemical ablation for treatment of cancer will be performed.
Preoperative clinic chart, procedure note, postoperative chart, pre- and post-operative CT, MRI or Ultrasound, angiographic findings, biopsy results and pathologic findings, will be reviewed. Patient survival, treatment responses, complications after the therapy will be collected from clinic visits and clinical encounters.
Patient overall performance status before and after procedures will be assessed using the Quality of Life questionnaire (SF-36™ Health Survey).
|Study Type :||Observational|
|Actual Enrollment :||26 participants|
|Official Title:||Prospective Analysis of Percutaneous Ablations for Cancer Treatment|
|Study Start Date :||February 2012|
|Primary Completion Date :||January 2014|
|Study Completion Date :||January 2014|
- Effect of percutaneous and transarterial treatments for cancer in quality of life [ Time Frame: 1 year ]Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.
- response rate to percutaneous and transarterial treatment for cancer [ Time Frame: 1 month, 3 months, 6 months, 1 year. ]Patients will be followed up 1, 3, 6 and 1year intervals after procedure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01563679
|United States, Georgia|
|Emory University Hospital|
|Altanta, Georgia, United States, 30322|
|Principal Investigator:||Hyun S Kim, MD||Emory University|